Icotrokinra: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •2 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Selective IL-23R blockade may reduce Th17-mediated immune defense against extracellular pathogens, particularly mucocutaneous candidiasis. No signal for serious infections has emerged in clinical trials.
Clinical trial data extend to approximately 52 weeks. Long-term effects of sustained daily oral IL-23R blockade on malignancy risk, cardiovascular outcomes, and immune function require ongoing surveillance.
⚠️Important Warnings
- •Icotrokinra is investigational and not approved by any regulatory authority
- •All efficacy and safety data are from clinical trials; real-world outcomes may differ
- •Long-term safety data beyond 52 weeks are still maturing
- •This information is for educational purposes only and does not constitute medical advice
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational. NDA submitted July 2025; FDA decision expected 2026. | - |
| European Union | Investigational. Regulatory submission anticipated. | - |
| Global | Not approved in any jurisdiction. Clinical trials ongoing in multiple countries. | - |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 25+ community reports
View community protocolsCritical Safety Information#
Icotrokinra (JNJ-2113) is an investigational medication that has not been approved by any regulatory authority worldwide. All information presented here is derived from published clinical trial data and press releases. This content is for educational and research reference purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Safety Profile#
Clinical Trial Safety Data#
Across the ICONIC Phase 3 program (ICONIC-LEAD, ICONIC-ADVANCE 1 & 2, ICONIC-TOTAL), icotrokinra has demonstrated a safety profile comparable to placebo:
- Overall adverse events: 49.1% icotrokinra vs 51.9% placebo (pooled data)
- Serious adverse events: Low incidence, no treatment-related signals identified
- Discontinuation due to adverse events: Low rates, similar between groups
- No serious infections attributed to icotrokinra
- No malignancies attributed to icotrokinra
- No major cardiovascular events attributed to icotrokinra
Comparison with Established Therapies#
Icotrokinra's safety profile compares favorably with other oral targeted therapies:
- Unlike JAK inhibitors, no signal for cardiovascular events, malignancy, or thrombosis
- Unlike broad immunosuppressants, selective IL-23R blockade preserves most immune functions
- No injection site reactions (unlike injectable biologics)
Risk-Benefit Analysis#
Potential Benefits#
- First oral peptide therapy for moderate-to-severe plaque psoriasis
- Eliminates the need for injections (patient preference, adherence)
- Selective IL-23R blockade with favorable safety profile
- Demonstrated superiority over deucravacitinib (the only other oral targeted therapy)
- Efficacy in difficult-to-treat sites (scalp, genitals)
Potential Risks#
- Immunosuppression: Theoretical reduction in Th17-mediated host defense; no clinical signal to date
- Unknown long-term effects: Data limited to approximately 52 weeks
- Novel mechanism: Receptor-side IL-23 blockade has no long-term clinical precedent (injectable mAbs target the ligand)
- Daily dosing requirement: Requires consistent daily adherence; missed doses may affect efficacy
Risk Mitigation#
- Thorough infection screening prior to treatment initiation
- Monitoring for signs of infection during treatment
- Avoidance of live vaccines
- Regular follow-up with dermatologist for disease activity and safety monitoring
Regulatory Status#
United States#
Johnson & Johnson submitted an NDA to the FDA in July 2025 for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older. The NDA was supported by data from four Phase 3 ICONIC trials. An FDA decision is expected in 2026.
European Union#
Regulatory submissions in Europe are anticipated but have not yet been publicly announced.
Other Markets#
Icotrokinra is currently in clinical development in multiple countries. No approvals exist in any jurisdiction.
Special Populations#
Adolescents (12-17 years)#
The ICONIC-LEAD trial included adolescent patients aged 12 and older. Separate subgroup analyses from this population have not been published in detail, but the overall trial met its primary endpoints in the combined adult and adolescent population.
Elderly Patients#
Specific data in elderly patients have not been separately reported, though older adults were included in the ICONIC trials. No dose adjustment for age has been recommended.
Pregnancy and Lactation#
No data are available regarding the use of icotrokinra during pregnancy or breastfeeding. Animal reproductive toxicology data have not been publicly disclosed. Women of childbearing potential should discuss family planning with their healthcare provider before considering treatment.
Hepatic and Renal Impairment#
Specific pharmacokinetic studies in hepatic or renal impairment populations have not been published. As a macrocyclic peptide, icotrokinra's metabolism and excretion profile may differ from small molecules and monoclonal antibodies.
Medical Disclaimer#
The information provided on this page is for educational and research purposes only. It is not intended to serve as medical advice, diagnosis, or treatment recommendation. Icotrokinra is an investigational compound not approved for any use. Clinical decisions should be made in consultation with a qualified healthcare provider who can consider individual patient circumstances.
Related Reading#
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.